Matinas BioPharma Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stock Based Compensation (Tables)

Stock Based Compensation (Tables)

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The Company recognized stock-based compensation expense (options, and restricted share grants) in its consolidated statements of operations as follows ($ in thousands):

	Year End December 31,
	2014		2013

Research and Development	$	397	$	82
General and Administrative		1,576		244
Total	$	1,973	$	326

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]

The following table contains information about the Company’s stock plan at December 31, 2014:

	Awards Reserved					Awards
	for		Awards			Available
	Issuance		Issued			for Grant
2013 Equity Compensation Plan		8,250,000		5,646,067	*		2,603,933

* includes both stock grants and option grants

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following table summarizes the Company’ stock option activity and related information for the years ended December 31, 2013and 2014 (number of options in thousands):

	Number of Options		Weighted average exercise price		Weighted average contractual term in years
Outstanding at December 31, 2012		-	$	-		-

Granted		3,160	$	0.94
Exercised		-
Forfeited		-
Expired		-

Outstanding at December 31, 2013		3,160	$	0.94		9.7

Granted		2,413	$	1.22
Exercised		-
Forfeited		(196)
Expired		(24)

Outstanding at December 31, 2014		5,353	$	1.06		9.1

	Year ended December 31,
	2014		2013
Options exercisable at end of year		2,460		321
Weighted average grant date fair value (per share) of options granted during the period	$	0.68	$	0.66

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The following weighted-average assumptions were used to calculate share based compensation for the full year ended:

	For the year ended December 31,
	2014			2013
Volatility		68.76	%		81.06	%
Risk-free interest rate		1.65% - 1.93	%		1.85% – 2.15	%
Dividend yield		0.0	%		0.0	%
Expected life		4.75 – 5.5 years			5.0 – 6.0 years

- Definition

Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan. Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.

+ References + Details